Community Bank & Trust Waco Texas cut its stake in Celgene Corporation (NASDAQ:CELG) by 0.1% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 22,449 shares of the biopharmaceutical company’s stock after selling 20 shares during the period. Celgene Corporation makes up approximately 1.9% of Community Bank & Trust Waco Texas’ holdings, making the stock its 11th largest position. Community Bank & Trust Waco Texas’ holdings in Celgene Corporation were worth $3,793,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Marietta Wealth Management LLC bought a new stake in Celgene Corporation during the fourth quarter valued at $481,000. Greenwood Capital Associates LLC boosted its stake in Celgene Corporation by 1.9% in the fourth quarter. Greenwood Capital Associates LLC now owns 10,145 shares of the biopharmaceutical company’s stock valued at $1,174,000 after buying an additional 190 shares during the period. Azimuth Capital Management LLC boosted its stake in Celgene Corporation by 37.6% in the fourth quarter. Azimuth Capital Management LLC now owns 83,096 shares of the biopharmaceutical company’s stock valued at $9,618,000 after buying an additional 22,724 shares during the period. Polen Capital Management LLC boosted its stake in Celgene Corporation by 27.0% in the fourth quarter. Polen Capital Management LLC now owns 4,352,572 shares of the biopharmaceutical company’s stock valued at $503,810,000 after buying an additional 926,521 shares during the period. Finally, Lyell Wealth Management LP bought a new stake in Celgene Corporation during the fourth quarter valued at $2,015,000. Institutional investors and hedge funds own 78.41% of the company’s stock.

Shares of Celgene Corporation (NASDAQ:CELG) traded down 1.31% on Tuesday, reaching $135.27. 2,836,602 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $133.32 and a 200-day moving average price of $123.59. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $139.00. The company has a market cap of $105.83 billion, a PE ratio of 41.89 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. During the same period last year, the business earned $1.44 EPS. The company’s revenue was up 18.7% compared to the same quarter last year. Equities research analysts anticipate that Celgene Corporation will post $7.32 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Community Bank & Trust Waco Texas Sells 20 Shares of Celgene Corporation (NASDAQ:CELG)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/08/community-bank-trust-waco-texas-sells-20-shares-of-celgene-corporation-nasdaqcelg-updated-updated-updated.html.

CELG has been the topic of several research reports. BTIG Research restated a “buy” rating and set a $138.00 price objective on shares of Celgene Corporation in a research report on Wednesday, May 24th. Argus upgraded shares of Celgene Corporation from a “hold” rating to a “buy” rating and raised their price objective for the company from $96.93 to $160.00 in a research report on Monday, July 31st. Jefferies Group LLC restated a “buy” rating and set a $160.00 price objective on shares of Celgene Corporation in a research report on Tuesday, July 11th. Zacks Investment Research cut shares of Celgene Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Finally, Cantor Fitzgerald set a $160.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 6th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and twenty-three have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $147.06.

In related news, insider Rupert Vessey sold 4,785 shares of the stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the transaction, the insider now directly owns 4,004 shares of the company’s stock, valued at approximately $481,200.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Robert J. Hugin sold 175,970 shares of the stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the completion of the transaction, the insider now directly owns 1,033,909 shares of the company’s stock, valued at $138,688,553.26. The disclosure for this sale can be found here. Insiders sold a total of 235,255 shares of company stock worth $31,377,042 over the last 90 days. Company insiders own 0.95% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.